Results 111 to 120 of about 99,547,245 (298)

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

open access: yesBMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen   +9 more
wiley   +1 more source

Correlation Between IFNγ+ and CTLA-4+ Tumor Infiltrating Lymphocytes In Luminal And Non-Luminal Breast Carcinoma

open access: yesQanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2019
The role of tumor infiltrating lymphocytes (TIL) in breast carcinoma depends on the molecular subtype, especially the expression of the estrogen receptor.
Irene Lingkan Parengkuan   +2 more
doaj   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

open access: yesChronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi   +2 more
wiley   +1 more source

CTLA-4 Engagement Inhibits Th2 but not Th1 Cell Polarisation

open access: yesClinical and Developmental Immunology, 2003
CTLA-4 deficient mice show severe lymphoproliferative disorders with T helper sub-population skewed toward the Th2 phenotype. In the present work, we investigated the role of CTLA-4 in T helper cell subset differentiation.
Vanessa Ubaldi   +4 more
doaj   +1 more source

Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies [PDF]

open access: yes, 2023
Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic; however, long-term benefit is limited to a subset of patients for select cancer indications.
Sansom, David M   +11 more
core  

Case Study of a Cross‐Platform Evaluation of an Optimized Multicolor Flow Cytometry Immunophenotyping Assay for Human Peripheral Whole Blood

open access: yesCytometry Part A, EarlyView.
ABSTRACT Flow cytometry is a commonly used single‐cell analysis technique that can be applied for the immunophenotyping of human blood samples. Nowadays, increasing numbers of clinical trials include translational research programs utilizing flow‐based immune monitoring assays to assess patients' longitudinal immune status.
Lia Mogge   +4 more
wiley   +1 more source

Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Spread: A Systematic Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris   +4 more
wiley   +1 more source

AGEN1884 binds CTLA-4 and blocks CTLA-4 from interacting with CD80 and CD86.

open access: yes, 2018
(A) Binding of fluorescently-labeled CD80-Fc or CD86-Fc (1 nM) in the presence of increasing concentrations of AGEN1884 or an IgG1 isotype control. Binding to CTLA-4-linked microspheres was assessed using Luminex. (B) CTLA-4-expressing CHO cells were pre-
Gerd Ritter (209869)   +26 more
core   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy